Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

Elevance Health, Inc. (ELV)

CIK 0001156039 2 material events

Insider activity (SEC Form 4)

Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.

Open-market · last 30 days: 2 buyers bought $1.4M 0 sellers sold $0
Open-market · last 90 days: 2 buyers bought $1.4M 2 sellers sold $827K
InsiderRoleDateTransactionSharesValue
BOUDREAUX GAIL President and CEO, Director 2026-07-17 Open-market buy 680 $249K
BOUDREAUX GAIL President and CEO, Director 2026-07-17 Open-market buy 2045 $753K
PERU RAMIRO G Director 2026-07-17 Open-market buy 1000 $366K
Penczek Ronald W CAO & Controller 2026-06-12 Open-market sell 369 $149K
Dixon Robert L JR Director 2026-06-11 Open-market sell 151 $61K
Penczek Ronald W CAO & Controller 2026-05-19 Option exercise 654 $177K
Penczek Ronald W CAO & Controller 2026-05-19 Option exercise 877 $273K
Penczek Ronald W CAO & Controller 2026-05-19 Open-market sell 1531 $617K
COLLIS STEVEN H Director 2026-05-13 Grant/award 563 $0
DeVore Susan D. Director 2026-05-13 Grant/award 563 $0
Dixon Robert L JR Director 2026-05-13 Grant/award 563 $0
HAY LEWIS III Director 2026-05-13 Grant/award 563 $0
Jallal Bahija Director 2026-05-13 Grant/award 563 $0
Neri Antonio F Director 2026-05-13 Grant/award 563 $0
PERU RAMIRO G Director 2026-05-13 Grant/award 563 $0
SCHULMAN AMY W Director 2026-05-13 Grant/award 563 $0
STRABLE-SOETHOUT DEANNA D Director 2026-05-13 Grant/award 563 $0
Schneider Ryan M. Director 2026-05-13 Grant/award 563 $0
SCHULMAN AMY W Director 2026-03-12 Open-market sell 26 $7K
Kendrick Charles Morgan JR EVP & President, Commercial 2026-03-06 Open-market sell 3196 $911K
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.

Earnings release

8-K filed 2026-07-15 confidence 98% Item 2.02

Elevance Health issued a press release on July 15, 2026, reporting second quarter 2026 financial results, including operating revenue of $49.8 billion, diluted EPS of $6.71, and adjusted diluted EPS of $7.45. The company also raised full-year 2026 guidance for diluted EPS to at least $20.10 and adjusted diluted EPS to at least $27.00. This is a standard quarterly earnings release with detailed financial statements, segment performance, and forward guidance—a material disclosure affecting investor assessment of the registrant's financial performance and outlook.

View raw filing on EDGAR →

Other material

8-K filed 2026-06-10 confidence 72% Item 7.01

The filing discloses reaffirmation of full-year 2026 earnings guidance ($19.85 per diluted share including unfavorable items; $26.75 adjusted) and benefit expense ratio guidance (90.2% ± 50 bps) during investor meetings. While this is forward-looking guidance rather than an earnings release (which typically reports historical results), the reaffirmation of specific quantitative earnings and operational metrics would materially affect a reasonable investor's assessment of the company's expected financial performance. This does not fit cleanly into earnings_release (no historical results reported) but is material guidance disclosure that warrants classification as other_material.

View raw filing on EDGAR →